Drug Trial Radar · NCT07801027
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 6, 2026
Primary completion
Jan 31, 2030
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess the safety of pembrolizumab with chemotherapy or chemoradiotherapy in participants in India for: * Advanced gastric or gastroesophageal junction \[GEJ\] cancer that is (human epidermal growth factor receptor 2 \[HER2\]-negative and has a programmed death-ligand 1 \[PD-L1\] combined positive score \[CPS\] ≥1 * Advanced and/or unresectable biliary tract cancer \[BTC\], and * High-risk, locally advanced cervical cancer
Conditions
- Neoplasm Malignant
- Gastric Neoplasms
- Gastroesophageal Junction Adenocarcinoma
- Biliary Tract Carcinoma
- Uterine Cervical Neoplasms
Interventions
PembrolizumabBiological
Administered as an IV infusion
CisplatinDrug
Administered as an IV infusion
5-FluorouracilDrug
Administered as an IV infusion
OxaliplatinDrug
Administered as an IV infusion
CapecitabineDrug
Administered as an oral tablet
GemcitabineDrug
Administered as an IV infusion
External Beam RadiotherapyRadiation
External beam radiation per the Radiation Manual
BrachytherapyRadiation
Internal radiation - brachytherapy per the Radiation Manual
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced One or More Adverse Events (AEs)Time frame: Up to approximately 27 months
- Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.